CellProthera sets the scene for Phase III stem cell therapy trial

CellProthera sets the scene for Phase III stem cell therapy trial

The biotech will soon evaluate the safety and efficacy of its regenerative cardiovascular stem cells, coined ProtheraCytes, in a Phase III trial.

Arena | March 17, 2026 – Annabel Kartal Allen

Read on line